Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome

Abstract This randomized clinical trial evaluates the efficacy and safety of 2 doses of a pharmaceutical formulation of cannabidiol vs placebo for adjunctive treatment of convulsive seizures in patients with Darvet syndrome. Authors: Ian Miller, Ingrid E. Scheffer, Boudewijn Gunning, Rocio Sanchez-Carpintero, Antonio Gil-Nagel, M. Scott Perry, Russell P. Saneto, Daniel Checketts, Eduardo Dunayevich, Volker Knappertz Affiliations: Department of Neurology, Nicklaus Children’s Hospital, Miami, Florida; Epilepsy Research Centre, The University of Melbourne at Austin Health and the Royal Children’s Hospital,